November 16, 2023 How our collaboration with CGT Catapult and Refeyn aims to refine the efficiency of AAV Manufacturing
Our Business Development Technical Expert at our ATMP facility in Stevenage, Yatindra Tirunagari, was invited by The Medicine Maker to talk about our recent collaboration with the Cell and Gene Therapy (CGT Catapult) and Refeyn, aiming at improving AAV manufacturing by developing and applying advanced process analytical technologies (PAT).
AAV production is complex and time-consuming, partly due to current analytical methods mainly relying on manual methods. The use of automated analytical technologies will allow us to assess the improvements in productivity and AAV yield, reducing processing bottlenecks and enhancing process reproducibility and batch-to-batch comparability.
If you would like to learn more about our collaboration with CGT Catapult and Refeyn and how it aims to improve the efficiency of AAV manufacturing, you can find the full article here: https://themedicinemaker.com/manufacture/enhancing-aav-manufacture-with-digital-twins
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Senior Director Corporate Communication